US 10143702
Fixed-dose pharmaceutical composition comprising rifabutin, clarithromycin, and clofazimine
granted A61KA61K31/395A61K31/435
Quick answer
US patent 10143702 (Fixed-dose pharmaceutical composition comprising rifabutin, clarithromycin, and clofazimine) held by RedHill Biopharma Ltd. expires Mon Nov 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- RedHill Biopharma Ltd.
- Grant date
- Tue Dec 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 5
- CPC classes
- A61K, A61K31/395, A61K31/435, A61K31/438, A61K31/44